What the FDA labels say about taking them together
Quinapril and temsirolimus
Quinapril's FDA label of December 14, 2023 names temsirolimus in its warnings section; temsirolimus's label does not name quinapril itself but warns about its class (ACE inhibitors). The quinapril label: “Patients taking concomitant mammalian target of rapamycin (mTOR) inhibitor (e.g., temsirolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema.”
Check it at the source: the quinapril FDA label on DailyMed (effective December 14, 2023, Lupin Pharmaceuticals, Inc.); the temsirolimus FDA label on DailyMed (effective December 26, 2025, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.).
What does the quinapril label say about temsirolimus?
Quinapril label, warningsPatients taking concomitant mammalian target of rapamycin (mTOR) inhibitor (e.g., temsirolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema.
Source: FDA drug label (Quinapril), Lupin Pharmaceuticals, Inc., effective December 14, 2023 (SPL set 8ded0773-3aec-4e89-9836-d22a5a84abf0), via openFDA; the full label on DailyMed
What does the temsirolimus label say about quinapril?
Temsirolimus's label does not name quinapril itself; it warns about its class (ACE inhibitors):
Temsirolimus label, drug interactionsIf alternative treatment cannot be administered, a dose adjustment should be considered [see Dosage and Administration (2.4) ]. Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine.
Temsirolimus label, drug interactionsMonitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).
Source: FDA drug label (Torisel), NDA022088 (Pf Prism Cv), as published by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., effective December 26, 2025 (SPL set 95b7dc92-2180-42f1-8699-3c28f609e674), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Quinapril | Temsirolimus | |
|---|---|---|
| Labeled for | High blood pressure, Heart failure | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once